The therapeutic potential of neuropeptide Y in cardiovascular disease

Bibliography

• TATEMOTO K, CARLQUIST M, MUTT V: Neuropeptide Y: a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature (1982) 296:659-660. The first description of neuropeptide Y.
   Google Scholar
• MUNGLANI R, HUDSPITH M, HUNT SP: The therapeutic potential of NPY: analgesic, anxiolytic and antihyper-tensive. Drugs (1996) 52:371-389. A recent and comprehensive overview of NPY with emphasis on its role in chronic pain.
   Google Scholar
• LUNDBERG JM, MODIN A, MALSTROM RE: Recent devel-opments in neuropeptide Y receptor antagonists. Trends Pharmacol Sci. (1996) 17:301-304. A useful update on the current state of NPY Yl antagonist develop-ment.
   Google Scholar
• PLAYFORD RJ, COX, HM: Peptide YY and neuropeptideY: two peptides intimately involved in electrolyte ho-meostasis. Trends Pharmacol Sci. (1996) 17:436–438.
   PubMed Web of Science ®Google Scholar
• WAHLESTEDT C, REIS DJ: Neuropeptide Y-related pep-tides and their receptors - are the receptors potential therapeutic drug targets? Ann. Rev. Pharmacol Toxicol (1993) 32:309-352. A major review from one of the leading groups on NPY receptor pharmacology.
   Google Scholar
• GRUNDEMAR L, HAKANSON R: Neuropeptide Y effectorsystems: perspectives for drug development. Trends Pharmacol. Sci. (1994) 15:153–159.
   PubMed Web of Science ®Google Scholar
• HERZOG H, HORT YJ, BALL HJ et al.: Cloned humanneuropeptide Y receptor couples to two different sec-ond messenger systems. Proc. Natl. Acad. ScL USA (1992) 89:5794–5798.
   PubMed Web of Science ®Google Scholar
• LARHAMMAR D, BLOMQVIST AG, YEE F et al: Cloning andfunctional expression of a human neuropeptide Y1 peptide YY receptor of the Y1 type. J. Biol. Chem. (1992) 267:10935–10938.
   PubMed Web of Science ®Google Scholar
• GERALD C, WALKER MW, VAYSSE PJJ et al.: Expressioncloning and pharmacological characterization of a hu-man hippocampal neuropeptide Y/peptide YY Y2 re-ceptor subtype. J. Biol. Chem. (1995) 270:26758–26761.
   PubMed Web of Science ®Google Scholar
• ROSE PM, FERNANDES P, LYNCH J et al: Cloning andfunctional expression of a cDNA encoding a human type 2 neuropeptide Y receptor. J. Biol. Chem. (1995) 270:22661–22664.
   PubMed Web of Science ®Google Scholar
• GEHLERT DR, BEAVERS IS, JOHNSON D et al: Expressioncloning of a human brain neuropeptide Y Y2 receptor. Mol. Pharmacol. (1996) 49:224–228.
   PubMed Web of Science ®Google Scholar
• BARD JA, WALKER MW, BRANCHEK TA et al: Cloning andfunctional expression of a human Y4 subtype receptor for pancreatic polypeptide, neuropeptide Y, peptide YY. j Biol. Chem. (1995) 270:26762–26765.
   PubMed Web of Science ®Google Scholar
• GERALD C, WALKER MW, CRISCIONE Let al.: A receptor subtype involved in neuropeptide Y induced food in-take. Nature (1996) 382:168–171.
   Google Scholar
• VVEINBERG DH, SIRINATHSINGHJI DJS, TAN CP et al: Cloning and expression of a novel neuropeptide Y receptor. J. Biol. Chem. (1996) 271:16435–16438.
   PubMed Web of Science ®Google Scholar
• RIMLAND J, XIN W, SWEETNAM P et al.: Sequence and expression of a neuropeptide Y receptor cDNA. Mol. Pharmacol (1991) 40:869–875.
   PubMed Web of Science ®Google Scholar
• JAZIN EE, Y00 H, BLOMQVIST AG et al.: A proposed bovine neuropeptide Y (NPY) receptor cDNA clone, or its human homologue, confers neither NPY binding sites nor NPY responsiveness ontransfecte d cells. Regu-latory Peptides (1993) 47:247–258.
   Google Scholar
• HIGUCHI H, COSTA E, YANG HYT: Neuropeptide Y in-hibits the nicotine-mediated release of catecholamines from bovine adrenal chromatin cells. J. Pharmacol. Exp. 7her. (1988) 244:468–474.
   PubMed Web of Science ®Google Scholar
• JAQUES D, CADIEUX A, DUMONT Y et al: Apparent affinity potency of BIBP3226, a non-peptide neuropep-tide Y receptor antagonist on purported neuropeptide Y Yi, Y2 and Y3 receptors. Eur. j Pharmacol. (1995) 278:R3–R5.
   PubMed Web of Science ®Google Scholar
• FUXE K, AGNATI LF, HARF STRAND A eta].: On the role of neuropeptide Yin information handling in the central nervous system in normal and physiopathological states. Focus on volume transmission and neuropep-tide Y/alpha 2 receptor interactions. Ann. NY Acad. Sci. (1990) 579:28–67.
   Google Scholar
• TABARIN A, CASSIEDE P, MINOT AP et al.: Heterogeneity of neuropeptide Y immunoreactivity in patients with pheochromocytoma: influence on the diagnostic power measuring plasma NPY using antisera with dif-ferent specificities. Acta Endocrinol (1993) 128:243–250.
   PubMedGoogle Scholar
• MICHEL MC, BUSCHAUER A: Neuropeptide Y and itsantagonists. Drugs Future (1992) 17:39–45.
   Google Scholar
• VVESTLIND DANIELSSON A, UNDEN A, ABENS J et al:Neuropeptide Y receptors and the inhibition of adeny-late cyclase in the human frontal temporal cortex. Neurosci. Leff. (1987) 74:237–242.
   PubMed Web of Science ®Google Scholar
• AAKERLUND L, GETHER U, FUHLENDORFF J et al.: Y1 receptors for neuropeptide Y are coupled to mobiliza-tionofintracellular calcium and inhibition of adenylate cyclase. FEBS Lett (1990) 260:73–78.
   PubMed Web of Science ®Google Scholar
• COLMERS WF, BLEAKMAN D: Effects of neuropeptide Y on the electrical properties of neurons. Trends Neurosci. (1994) 17:373-379. A comprehensive overview of the electrop hysiologic al effects of Yl, Y2 and Y3 receptor activation in neurones.
   Google Scholar
• HUNT SP, EMSON PC, GILBERT R eta].: Presence of avian pancreatic polypeptide-like immunoreactivity in cate cholamine and met hi o nine-e nkep halin-conta ini ng neurones within the central nervous system. Neurosci. Leff. (1981) 21:125–130.
   Google Scholar
• ALLEN JM, GIBSON SJ, ADRIAN TE et al: Neuropeptide Y in human spinal cord. Brain Res. (1984) 308:145–148.
   PubMed Web of Science ®Google Scholar
• DAVVBARN D, HUNT SP, EMSON PC: Neuropeptide Y: regional distribution, chromatographic charac-terization and immunohistochemical demonstration in post-mortemhumanbrain. Brain Res. (1984) 296:168–173.
   PubMed Web of Science ®Google Scholar
• BROWN BJ: Neuronal localisation and neuropeptide Ygene expression in the rat brain. J. Comp. Neurol (1989) 290:358–368.
   PubMed Web of Science ®Google Scholar
• SUNDLER F, BOTTCHER G, EKBLAD E eta].: PP, PYY and
   Google Scholar
• •NPY. Occurrence and distribution in the periphery. In: The Biology of Neuropeptide Y and Related Peptides Colmers WF,Wahlstedt C (Eds.), Humana Press (1993):157–196. A comprehensive review of the distribution of the pancreatic polypeptide family in the peripheral nervous system.
   Google Scholar
• PERNOW J, SCHWIELER J, KAHAN T et al: Influence of sympathetic discharge pattern on norepinephrine and neuropeptide Y release. Am. J. Physiol (1989) 257:H866-H872. Key demonstration of preferential release of noradrenaline at low frequency and NPY at high frequency discharge rates in sympathetic neurones.
   Google Scholar
• LUNDBERG JM, FRANCOCERECEDA A, LACROIX JS eta].:Neuropeptide Y and sympathetic neurotransmission. Ann. NY Acad. Sci. (1990) 611:166–174.
   PubMed Web of Science ®Google Scholar
• HAASS M, CHENG B, RICHARDT G etal.: Characterizationand presynaptic modulation of stimulation-evoked exocytotic co-release of noradrenaline and neuropep-tide Yin guinea pig heart. Naunyn-Schmied. Arch. Phar-macol. (1989) 339:71–78.
   Google Scholar
• PERNOW J, LUNDBERG JM: Modulation of noradrenalineand neuropeptide Y (NPY) release in the pig kidney in vivo: involvement of alpha2, NPY and angiotensin II receptors. Naunyn-Schmied. Arch. Pharmacol (1989) 340:379–385.
   PubMed Web of Science ®Google Scholar
• MARTIRE M, PISTRITTO G, MORES N et al.: Presynaptic a2-adrenoceptors and neuropeptide Y Y2 receptors inhibit [3H]noradrenaline release from rat hypotha-lamic synaptosomes via different mechanisms. Neuro-sci. Lett. (1995) 188:9–12.
   PubMed Web of Science ®Google Scholar
• POTTER EK, MITCHELL L, MCCLOSKEY MJD eta].: Pre- and postjunctional actions of neuropeptide Y and related peptides. Regulator)/ Peptides (1989) 25:167–177.
   Google Scholar
• GRUNDEMAR L, GRUNDSTROM N, JOHANSSON IGM eta].: Suppression by neuropeptide Y of capsaicin-sensitive sensory nerve-mediated contraction in guinea-pig air-ways. Br. J. Pharmacol (1990) 99: 473–476.
   Google Scholar
• GRUNDEMAR L, WAHLESTEDT C, WANG ZY: Neuropep-tide Y suppresses the neurogenic inflammatory re-sponse in the rabbit eye; mode of action. Regulatory Peptides (1993) 43:57–64.
   PubMed Web of Science ®Google Scholar
• VAYSSE PJ-J, WALKER MW, GERALD C et al: NPY, PYY orPP alter cAMP and Ca++ in cells expressing cloned human Y2 or Y4 receptors. Soc. Neurosci. AbsTh (1995) 21:1596.
   Google Scholar
• GRAY TS, MORLEY JE: Neuropeptide Y: anatomical dis-tribution and possible function in mammalian nervous system. Life Sci. (1986) 38:389–401.
   PubMed Web of Science ®Google Scholar
• GHILARDI JR, ALLEN CJ, VIGNA SR eta].: Cholecystokinin and neuropeptide Y receptors on single rabbit vagal afferent ganglion neurons: site prejunctional modula-tion of visceral Ensory neurons. Brain Res. (1994) 633:33–40.
   Google Scholar
• DUMONT Y, FOURNIER A, ST PIERRE S etal: Comparativecharacterization and autoradiographic distribution of neuropeptide Y receptor subtypes in the rat brain. J. Neurosci. (1993) 13:73–86.
   PubMed Web of Science ®Google Scholar
• DUMONT Y, FOURNIER A, ST PIERRE S et al.: Charac- terization of neuropeptide Y binding sites in rat brain membrane preparations using (1250 (Leu31,Pro34) pep-tide YY and (1251) peptide YY3-36 as selective Y1 and Y2 radioligands. j Pharmacol Exp. Ther. (1995) 272:673–680.
   Google Scholar
• MICHEL MC, LEWELJOHANN K, FARKE W etal: Regulation of NPY/NPY Y1 receptor/G protein system in rat brain cortex. Am. J. Physiol. (1995) 268:R192–R200.
   PubMed Web of Science ®Google Scholar
• GLAUM SR, MILLER RJ, RHIM H et al.: Characterization of Y3-receptor mediated synaptic inhibition by chimaeric neuropeptide Y-peptide YY peptides in the rat brain-stem. Br. J. Pharmacol (1997) 120:481–487.
   PubMed Web of Science ®Google Scholar
• SHINE J, POTTER EK, BIDEN T et al.: Neuropeptide Y regulation of the cardiovascular system. J. Hypertension (1994) 12:541-S45. A thorough evaluation of the regulatory role of NPY in the control of systemic blood pressure.
   Google Scholar
• MICHEL MC, RASCHER W: Neuropeptide Y: a possible role in hypertension? J Hypertension (1995) 13:385–395.
   Google Scholar
• © Ashley Publications Ltd. All rights reserved.
   Google Scholar
• MCAULEY MA, CHEN X, WESTFALL TC: Central cardiovas-cular actions neuropeptide Y. In: The Biology of Neuropep-tide Y and Related Peptides. Colmers WF, Wahlstedt C (Eds.), Humana Press (1993):389–418.
   Google Scholar
• MODIN A, PERNOW J, LUNDBERG JM: Evidence for two neuropeptide Y receptors mediating vasoconstriction. Eur. j Pharmacol. (1991) 203:165–171.
   PubMed Web of Science ®Google Scholar
• GRUNDEMAR L, JONAS SE, MORNER N et al.: Characterization of vascular neuropeptide Y receptors. Br. J. Pharmacol (1992) 105:45-50. Demonstration that the NPY-evoked pressor response is primarily mediated via vascular Y1 receptors.
   Google Scholar
• TESSEL RE, MILLER DW, MISSE GA eta].: Characterization of vascular postsynaptic NPY receptor function and regulation and differential sensitivity of Y1 and Y2 receptor function to changes in extracellular calcium availability and prior in vitro peptide exposure. Neuropeptides (1993) 25:289–298.
   Google Scholar
• LUNDBERG JM, MODIN A: Inhibition of sympathetic vasoconstriction in pigs in vivo by the neuropeptide Y-Y1 receptor antagonist BIBP 3226. Br. J. Pharmacol (1995) 116:2971–2982.
   PubMed Web of Science ®Google Scholar
• EDVINSSON L, EKBLAD E, HAKANSON R etal: Neuropep-tide Y potentiates the effect of various vasoconstrictor agents on rabbit blood vessels. Br. J. Pharmacol (1984) 83:519–525.
   PubMed Web of Science ®Google Scholar
• MCAULEY MA, MACRAE IM, REID JL: The cardiovascularactions of clonidine and neuropeptide-Y in the ventro-later al medulla of the rat. Br. J. Pharmacol (1989) 97:1067–1074.
   PubMed Web of Science ®Google Scholar
• MACRAE IM, DEWAR D, REID JL eta].: Specific alterationsin cardiovascular function and in glucose utilisation within lower brainstem nuclei following intracisternal neuropeptide Y in the conscious rat. Brain Res. (1990) 515:99–103.
   Google Scholar
• GRUNDEMAR L, WAHLESTEDT C, REIS DJ: Long-lasting inhibition ofthe cardiovascular responses to glutamate and the baroreceptor reflex elicited by neuropeptide Y injected into the mcleus tractus solitarius of the rat. Neurosci. Lett. (1991) 122:135–139.
   PubMed Web of Science ®Google Scholar
• SHIH CD, CHAN JYH, CHAN SHH: Tonic suppression of baroreceptor reflex response by endogenous neuro- peptide Y at the nucleus tractus solitarius of the rat. Neurosci. Lett (1992) 148:169–172.
   PubMed Web of Science ®Google Scholar
• YANG SN, NARVAEZ JA, BJELKE B et al.: Microinjections of subpicomolar amounts of NPY(13-36) into the nu-cleus tractus solitarius of the rat counteract the vasode-pressor responses of NPY(1-36) and of a NPY Y1 receptor agonist. Brain Res. (1993) 621:126–132.
   PubMed Web of Science ®Google Scholar
• YANG SN, FIOR DR, HEDLUND PB et al.: Selective modu-lation of the NPY receptors of the Y2 subtype by alpha2 receptors in the nucleus tractus solitarii of the rat. A cardiovascular and quantitative receptor autoradiog-raphical analysis. Brain Res. (1994) 654:137–144.
   Google Scholar
• YANG SN, FIOR DR, HEDLUND PB eta].: Coinjections of NPY(1–36) or (Leu31,Pro34)NPY with adrenaline in the nucleus tractus solitarius of the rat counteract the vasodepressor responses to adrenaline. Neurosci. Lett. (1994) 171:27–31.
   Google Scholar
• YANG SN, BJELKE B, NARVAEZ JA et al.: Counteraction ofNPY-induced c-Fos expression in the nucleus tractus solitarii by alpha2 receptor agonists. Neut. eport (1995) 6:384–388.
   Google Scholar
• WHARTON J, POLAK JM: Neuropeptide tyrosine in thecardiovascular system. Ann. NY Acad. Sci. (1990) 611:133–144.
   PubMed Web of Science ®Google Scholar
• MCDERMOTT BJ, MILLAR BC, PIPER HM: Cardiovascular effects of neuropeptide Y: receptor interactions and cellular mechanisms. Cardiovasc. Res. (1993) 27:893–905.
   PubMed Web of Science ®Google Scholar
• MILLAR BC, WEIS T, PIPER HM etal: Positive and negative contractile effects of neuropeptide Y on ventricular myocytes. Am. J. Physiol. (1991) 261:H1727-H1733. Demonstration that the conflicting positive and negative effects of NPY on myocardium may be a consequence of species differences in ion channel function.
   Google Scholar
• WHARTON J, GORDON L, BYRNE J et al.: Expression of the human neuropeptide tyrosine Y1 receptor. Proc. Natl. Acad. Sci. USA (1993) 90:687–691.
   PubMed Web of Science ®Google Scholar
• SHEIKH SP, SHEIKH MI, SCHWARTZ TW: Y2-type recep-tors for peptide YY on renal proximal tubular cells in the rabbit. Am. J. Physiol. (1989) 257:F978–F984.
   PubMed Web of Science ®Google Scholar
• HACKENTHAL E, AKTORIES K, JAKOBS KH et al.: Neuropeptide Y inhibits renin release by a pertussis toxin-sensitive mechanism. Am. J Physic]. (1987) 252: F543–F550.
   Web of Science ®Google Scholar
• SMYTH DD, BLANDFORD DE, THOM SL: Disparate effectsof neuropeptide Y and clonidine on the excretion of sodium and water in the rat. Eur. j Pharmacol (1988) 152:157–162.
   PubMed Web of Science ®Google Scholar
• PLAYFORD RJ, MEHTA S, UPTON P eta].: Effect of peptide
   Google Scholar
• •YY on human renal function. Am. J Physiol. (1995) 268:F754-F759. In human volunteers, PYY causes natriuresis and diuresis at doses that have insignificant effect upon systemic arterial pressure.
   Google Scholar
• SOLT V, BROWN M, KENNEDY B et al.: Elevated insulin, norepinephrine and neuropeptide Y in hypertension. Am. J. Hypertension (1990) 3:823-828. First clinical report of significant elevation of plasma NPY levels in essential hypertensive patients.
   Google Scholar
• LETTGEN B, WAGNER S, HANZE J eta].: Elevated plasma concentration of neuropeptide Y in adolescents with primary hypertension. J. Human Hypertension (1994) 8:345–349. nypertensionr J. Hypertension k_mo) is:sszso-sso.
   Google Scholar
• WOCIAL B, IGNATOWSKASWITALSKA H, PRUSZCZYK P et al: Plasma neuropeptide Y and catecholamines in women and men with essential hypertension. Blood Pressure (1995) 4:143–147.
   PubMedGoogle Scholar
• EDVINSSON L, EKMAN R, THULIN T: Increased plasma levels of neuropeptide Y-like immunoreactivity and catecholamines in severe hypertension remain after treatment to normotension in man. Regulatory Peptides (1991) 32:279–287.
   PubMed Web of Science ®Google Scholar
• ERLINGE D, EKMAN R, THULIN T et al.: Neuropeptide Y-like immunoreactivity and hypertension. J. Hyperten-sion (1992) 10:1221–1225.
   PubMed Web of Science ®Google Scholar
• TABARIN A, MINOT AP, DALLOCHIO M et al: Plasma concentration of neuropeptide Yin patients with adre-nal hypertension. Regulatory Peptides (1992) 42:51–61.
   PubMed Web of Science ®Google Scholar
• VEGII0 F, SCHIAVONE D, MENGOZZI G et aL: Levels of plasma neuropeptide Y and other vasoactive sub-stances during head up tilt in normal and essential hypertensive subjects. Clin. Auto. Res. (1995) 5:67–70.
   PubMed Web of Science ®Google Scholar
• LUNDBERG JM, HEMSEN A, FRIED G et al.: Co-release of neuropeptide Y (NPY)-Iike immunoreactivity and catecholamines in newborn infants. Acta Physiol. Scand. (1986) 126:471–473.
   PubMedGoogle Scholar
• LUNDBERG JM, RUDEHILL A, SOLLEVI A et al: Frequency-and reserpine-dependent chemical coding of sympa-thetic transmission: differential release of norad-renaline and neuropeptide Y from pig spleen. Neurosci. Leff. (1986) 63:96–100.
   PubMed Web of Science ®Google Scholar
• LIND H, BRUDIN L, CASTENFORS J et al: The effects of alpha-trinositol on haemodynamic variables and neuropeptide Y levels in a pilot study of hypertensive healthy volunteers. Blood Pressure (1994) 3:242–247.
   PubMedGoogle Scholar
• PRUSZCZYK P, CHLEBUS M: Plasma neuropeptide Y during dynamic exercise in patients with essential hypertension. Clin. Exp. Hypertension (1995) 17:769–785.
   PubMed Web of Science ®Google Scholar
• MACCARRONE C, JARROTT B: Differences in regional brain concentrations of neuropeptide Y in spontane-ously hypertensive (M) and Wistar-Kyoto (WKY) rats. Brain Res. (1985) 345:165–169.
   PubMed Web of Science ®Google Scholar
• AGUIRRE JA, HEDLUND PB, NARVAEZ JA eta].: Increased vasopressor actions of intraventricular neuropeptide Y-(13–36) in spontaneously hypertensive vs. nor-motensive Wistar-Kyoto rats. Possible relationship to increases in Y2 receptor binding in the nucleus tractus solitarius. Brain Res. (1995) 684:159–164.
   Google Scholar
• GRUNDEMAR L, HAKANSON R: Multiple neuropeptide Y receptors are involved in cardiovascular regulation. Peripheral and central mechanisms. Gen. Pharmacol (1993) 24:785–796.
   PubMedGoogle Scholar
• ZUKOWSKAGROJEC Z, GOLCZYNSKA M, SHEN GH et al.: Modulation of vascular function by neuropeptide Y during development of hypertension in spontaneously hypertensive rats. Paediat. Nephrol. (1993) 7:845–852.
   PubMed Web of Science ®Google Scholar
• OGAWA T, KITAMURA K, KANGAWA K et al.: Platelet neuropeptide Y in spontaneously hypertensive rats. J. Hypertension (1992) 10:765–771.
   PubMed Web of Science ®Google Scholar
• KATSUYA T, HIGAKI J, ZHAO Y et al: A neuropeptide Y locus on chromosome 4 cosegregates with blood pres-sure in the spontaneously hypertensive rat. Biochem. Biophysical Res. Comm. (1993) 192:261-267. Evidence for genetic linkage between NPY and hypertension in the spontaneously hypertensive rat.
   Google Scholar
• FAN XM, HENDLEY ED, FOREHAND CJ: Enhanced vascu-lar neuropeptide Y-immunoreactive innervation in two hypertensive rat strains. Hypertension (1995) 26:758–763.
   PubMed Web of Science ®Google Scholar
• SHIGERI Y, FUJIMOTO M: Neuropeptide Y stimulates DNA synthesis in vascular smooth muscle cells. Neuro-sci. Lett. (1993) 149:19–22.
   PubMed Web of Science ®Google Scholar
• ZUKOWSKAGROJEC Z, PRUSZCZYK P, COLTON C et al: Mitogenic effect of neuropeptide Y in rat vascular smooth muscle cells. Peptides (1993) 14:263–268.
   PubMed Web of Science ®Google Scholar
• MAISEL AS, SCOTT NA, MOTULSKY HJ et al: Elevation of plasma neuropeptide Y levels in congestive heart fail-ure. Am. J. Med. (1989) 86:43-48. First report of the association between elevated venous plasma NPY levels and left ventricular failure.
   Google Scholar
• NICHOLLS DP, RILEY M, ELBORN JS et al: Regulatory peptides in the plasma of patients with chronic cardiac failure at rest and during exercise. Eur. Heart (1992) 13:1399–1404.
   PubMed Web of Science ®Google Scholar
• ULLMAN B, JENSEN-URSTAD M, HULTING J et al.: Neuropeptide Y, noradrenaline and invasive haemody-namic data in mild to moderate chronic congestive heart failure. Clin. Physiol (1993) 13:409–418.
   PubMedGoogle Scholar
• FENG QP, HEDNER T, ANDERSSON B et al.: Cardiac neuropeptide Y and noradrenaline balance in patients with congestive heart failure. Br. Heart J. (1994) 71:261–267.
   PubMedGoogle Scholar
• ULLMAN B, LINDVALL K, LUNDBERG JM et al: Response of plasma neuropeptide Y noradrenaline to dynamic exercise and ramipril treatment in patients with con-gestive heart failure. Clin. Physiol. (1994) 14:123–134.
   PubMedGoogle Scholar
• RUDEHILL A, SOLLEVI A, FRANCOCERECEDA A et al.: Neuropeptide Y (NPY) and the pig heart release and coronary vasoconstrictor effects. Peptides (1986) 7:821–826.
   PubMed Web of Science ®Google Scholar
• MICHEL MC, WIRTH SC, ZERKOWSKI HR et al.: Lack of inotropic effects of neuropeptide Yin human myocar-dium. j Cardiovasc. Pharmacol. (1989) 14:919–922.
   PubMed Web of Science ®Google Scholar
• MALMSTROM RE, LUNDBERG JM: Neuropeptide Y ac-counts for sympathetic vasoconstriction in guinea-pig vena cava: evidence using BIBP 3226 3435. Eur. J. Phar-macol. (1995) 294:661–668.
   PubMed Web of Science ®Google Scholar
• KAHAN T, TADDEI S, PEDRINELLI R et al.: Noradrenergic sympathetic vascular control of the human forearm in hypertension: possible involvement of neuropeptide Y. J. Cardiovasc. Pharmacol. (1992) 19:587–592.
   PubMed Web of Science ®Google Scholar
• FUHLENDORFF J, GETHER U, AAKERLUND L et al.: (Leu31,Pro34) Neuropeptide Y: a specific Y1 receptor agonist. Proc. Natl. Acad. Sci. USA (1990) 87:182–186.
   PubMed Web of Science ®Google Scholar
• FETH F, ERDBRUGGER W, RASCHER W et al: Is PP56 (u-myo4nositol-1,2,6-triphosphate) an antagonist at neuropeptide Y receptors? Life Sci. (1993) 52: 1835-1844.
   Google Scholar
• RUDOLF K, EBELEIN W, ENGEL W et al: The first highly potent and selective non-peptide neuropeptide Y Y1 receptor antagonist: BIBP3226. Eur. J. Pharmacol. (1994) 271:R11-R13. The first report of a non-peptide NPY antagonist irhibiting NPY induced pressor reponses in the rat.
   Google Scholar
• TSENG A, INGLIS A, SELBIE LA et al.: Neuropeptide Y analog with selective antagonism effects mediated bypost junctional Y1 receptors. Eur. J. Pharmacol. (1994) 271:265–271.
   Google Scholar
• Report of a synthetic hexapeptide Y1 antagonist mediating pro-longed reduction in arterial pressure in spontaneously hypertensive rats.
   Google Scholar
• SERRADEIL LE GAL C, VALETTE G, ROUBY PE et al.:
   Google Scholar
• ••SR120819A, an orally-active and selective netunpeptideY Y1 receptor antagonist FEBS Lett. (1995) 362:192-196. First description of an orally active non-peptide Y1 antagonist.
   Google Scholar
• ABOUNADER R, VILLEMURE JG, HAMEL E: Charac-terization of neuropeptide Y (NPY) receptors in human cerebral arteries with selective agonists and the new Y1 antagonist MBP 3226. Br. J. Pharmacol (1995) 116:2245–50.
   PubMed Web of Science ®Google Scholar